
Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (JUNS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
juns · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 5 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Jupiter Neurosciences, Inc.You JUNS | $8M | N/A | — | — |
Aligos Therapeutics, Inc. ALGS | $32M | N/A | — | -$2.45 |
FibroGen, Inc. FGEN | $37M | 0.19x | — | $45.38 |
Genenta Science S.p.A. GNTA | $35M | N/A | — | -$0.32 |
Grace Therapeutics, Inc. GRCE | $37M | N/A | — | -$1.13 |
Kezar Life Sciences, Inc. KZR | $54M | N/A | — | -$7.66 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Jupiter Neurosciences, Inc. (JUNS) measures how much investors pay for each dollar of the company's trailing earnings. JUNS's current PE ratio of N/A is calculated by dividing its stock price of $0.23 by its TTM earnings per share of —.
Frequently asked questions
JUNS pe ratio · 6 questionsJUNS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.23 and TTM EPS of —. Data sourced from Financial Modeling Prep via JUNS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Jupiter Neurosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09